Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADMA 
ADMA Biologics Inc (ADMA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: ADMA (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $29.49
1 Year Target Price $29.49
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 144.75% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.36B USD | Price to earnings Ratio 21.76 | 1Y Target Price 29.49 |
Price to earnings Ratio 21.76 | 1Y Target Price 29.49 | ||
Volume (30-day avg) 3 | Beta 0.47 | 52 Weeks Range 10.21 - 25.67 | Updated Date 07/3/2025 |
52 Weeks Range 10.21 - 25.67 | Updated Date 07/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 45.01% | Operating Margin (TTM) 30.38% |
Management Effectiveness
Return on Assets (TTM) 22.06% | Return on Equity (TTM) 78.45% |
Valuation
Trailing PE 21.76 | Forward PE 28.99 | Enterprise Value 4341027222 | Price to Sales(TTM) 9.5 |
Enterprise Value 4341027222 | Price to Sales(TTM) 9.5 | ||
Enterprise Value to Revenue 9.45 | Enterprise Value to EBITDA 27 | Shares Outstanding 238734000 | Shares Floating 234169647 |
Shares Outstanding 238734000 | Shares Floating 234169647 | ||
Percent Insiders 2.58 | Percent Institutions 88.42 |
Upturn AI SWOT
ADMA Biologics Inc
Company Overview
History and Background
ADMA Biologics, Inc. was founded in 2004. The company focuses on the development and commercialization of human plasma-derived biologics for the treatment of immune deficiencies and prevention of certain infectious diseases. Initially focused on developing specialty plasma products, ADMA has expanded through acquisitions and organic growth.
Core Business Areas
- Plasma-Derived Biologics: ADMA develops and manufactures plasma-derived biologics, including intravenous immune globulin (IVIG) products for treating immunodeficient patients.
- Plasma Collection Centers: ADMA operates plasma collection centers to secure its plasma supply and control costs.
Leadership and Structure
Adam Grossman serves as President and Chief Executive Officer. The organizational structure includes departments for manufacturing, research and development, commercial operations, and plasma operations.
Top Products and Market Share
Key Offerings
- BIVIGAM: BIVIGAM is an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI). ADMA estimates single-digit market share of the IVIG market. Competitors include Grifols (GRFS), CSL Behring (CSLLY), and Takeda (TAK).
- ASCENIV: ASCENIV is an IVIG product indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents. ADMA estimates single-digit market share of the IVIG market. Competitors include Grifols (GRFS), CSL Behring (CSLLY), and Takeda (TAK).
Market Dynamics
Industry Overview
The plasma-derived biologics industry is characterized by high barriers to entry, stringent regulatory requirements, and reliance on a stable plasma supply. Demand is driven by increasing diagnosis rates and expanding treatment options.
Positioning
ADMA is positioned as a specialty player focused on niche IVIG products and direct control of its plasma supply. Its competitive advantage lies in its vertically integrated plasma collection network.
Total Addressable Market (TAM)
The global IVIG market is estimated to be in the billions of dollars annually. ADMA is positioned to capture a portion of this TAM through its specialized products and supply chain management.
Upturn SWOT Analysis
Strengths
- Vertically integrated plasma collection network
- Specialized IVIG products
- Strong relationships with patient advocacy groups
- Growing revenue
Weaknesses
- Limited market share compared to larger players
- High operating expenses
- Reliance on regulatory approvals
- Debt obligations
Opportunities
- Expanding indications for existing products
- Acquiring additional plasma collection centers
- Entering new geographic markets
- Developing novel plasma-derived therapies
Threats
- Competition from larger IVIG manufacturers
- Fluctuations in plasma supply
- Changes in reimbursement policies
- Adverse regulatory decisions
Competitors and Market Share
Key Competitors
- GRFS
- CSLLY
- TAK
Competitive Landscape
ADMA faces intense competition from larger, more established players. ADMA focuses on vertical integration of the plasma supply chain and specializes in niche products.
Growth Trajectory and Initiatives
Historical Growth: ADMA's historical growth is marked by increasing revenue driven by product sales. Financial data should be obtained from official reports. ADMA Biologics has been growing their revenue YOY.
Future Projections: Analyst projections suggest continued revenue growth as ADMA expands its market presence and optimizes its plasma collection network.
Recent Initiatives: Recent initiatives include expanding plasma collection capacity, pursuing new product approvals, and strengthening commercial partnerships.
Summary
ADMA Biologics is a growing biopharmaceutical company focused on plasma-derived biologics. Its strength lies in vertical integration and specialized products, but it faces competition from larger players. Increasing revenue and strategic initiatives suggest a positive trajectory but debt and regulatory risks remain. The company needs to continue to monitor their debt and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ADMA Biologics Inc
Exchange NASDAQ | Headquaters Ramsey, NJ, United States | ||
IPO Launch date 2013-10-17 | Co-Founder, President, CEO & Director Mr. Adam S. Grossman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 685 | Website https://www.admabiologics.com |
Full time employees 685 | Website https://www.admabiologics.com | ||
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.